Monday, 9 November 2026
Extreme specialist fees surge, Global Fund appoints new head, Intensive BP lowering trial
- 01
Extreme specialist fees rise as access pressures deepen
Specialist fees rose by 4% above inflation over the past year, according to a Grattan Institute analysis, while out-of-pocket costs for GP appointments and other Medicare services barely changed. In 2025, more than a quarter of patients who saw an out-of-hospital specialist paid an “extreme fee” of at least three times the Schedule Fee, up from fewer than one in 10 in 2015. More than 2.2 million Australians now pay at least one such fee each year, with the number increasing by about 250,000 annually; psychiatry and dermatology recorded some of the sharpest increases. Grattan attributed the trend to limited competition and specialist shortages, arguing that governments need tougher fee reforms and workforce planning as patients face high private costs or long public waitlists.
via The Medical Republic · also covered by The Conversation — Health
- 02
Global Fund appoints Mark Dybul as head
Mark Dybul was appointed head of the Global Fund. Health leaders hailed the appointment amid a rapidly changing global health landscape. The source gives limited detail about the leadership change.
via The Lancet
- 03
Trial examines intensive blood-pressure lowering in type 2 diabetes
A trial examined intensive blood-pressure lowering in patients with type 2 diabetes. It was published ahead of print in the New England Journal of Medicine. The supplied source gives no details on trial design, blood-pressure targets, outcomes or findings, so no clinical conclusions can be reported.
via NEJM
- 04
NEJM flags statin discontinuation in older adults without cardiovascular disease
Statin discontinuation in older adults without cardiovascular disease is the stated subject of an ahead-of-print New England Journal of Medicine item. The supplied source provides no study findings, participant details, methods or clinical conclusions. No effect of deprescribing on cardiovascular or other outcomes can be determined from the available text. The source gives limited detail.
via NEJM
- 05
Hyperaldosteronism remission report lacks supporting study details
Extended aldosterone synthase inhibition was linked in the title to hyperaldosteronism remission. However, the supplied ahead-of-print New England Journal of Medicine entry provides no abstract, methods, results, patient details or safety data. The source therefore gives insufficient detail to characterise the reported remission or its clinical significance.
via NEJM
- 06
AI mass surveillance raised as possible health determinant
Mass surveillance using artificial intelligence is being raised as a possible new determinant of health in the New England Journal of Medicine. The source provides no article content beyond the title and ahead-of-print status, so it gives limited detail about the argument, affected populations or clinical significance.
via NEJM
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.